936-47-0

Upstream product

• 104-55-2 3-phenyl-propenal 
• 14371-10-9 (E)-3-phenylpropenal 

Downstream Products

• 873-49-4 cyclopropylbenzene 
• 135614-40-3 (1R,3R)-1,3-Diphenyl-N,N'-bis-[1-phenyl-meth-(E)-ylidene]-propane-1,3-diamine 
• 135613-89-7 (1R^*,3R^*)-N,N'-dibenzyl-1,3-diphenyl-1,3-propanediamine 
• 142634-65-9 (3R,5R)-3,5-Diphenyl-pyrazolidine 
• 140868-00-4 (1R^*,3R^*)-N,N'-dimethyl-1,3-diphenyl-1,3-propanediamine 
• 126568-44-3 3-(N-tert-butoxycarbonylamino)-3-phenylpropanitrile 
• 140868-01-5 (1R^*,3R^*)-N,N'-diethyl-1,3-diphenyl-1,3-propanediamine 
• 140867-98-7 (1R^*,3R^*)-N,N'-bisformyl-1,3-diphenyl-1,3-propanediamine 
• 140868-02-6 (1R^*,3R^*)-N,N'-bis(1-methylethyl)-1,3-diphenyl-1,3-propanediamine 
• 140867-99-8 (1R^*,3R^*)-N,N'-bisacetyl-1,3-diphenyl-1,3-propanediamine 
• 140867-97-6 (3R^*,5R^*)-1-tert-butoxycarbonyl-3,5-diphenylpyrazolidine 
• 140868-03-7 (1R^*,3R^*)-N,N'-bis(2,2-dimethylpropyl)-1,3-diphenyl-1,3-propanediamine 
• 140888-99-9 (1R^*,3R^*)-N,N'-bis(2,4,6-trimethylphenylmethyl)-1,3-diphenyl-1,3-propanediamine 
• 124330-05-8 1-Ethoxycarbonyl-5-phenyl-2-pyrazoline 

Relevant academic research and scientific papers

BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF

Provided are a substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition, also disclosed are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.

RIPK1 INHIBITORS AND METHODS OF USE

The invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I) compounds act as RIPK1 inhibitors and may be useful in preventing, treating, or acting as a therapeutic agent against, diseases associated with RIPK1.

N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES

The N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide derivative exhibits excellent inhibitory activity against at least one kinase selected from the group consisting of ABL1, ABL2, AURKB, BRK, CDK11

Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase

RIP1 kinase regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including inflammatory and neurological diseases. Currently, RIP1 kinase inhibitors have advanced into early clinical trials for evaluation in inflammatory diseases such as psoriasis, rheumatoid arthritis, and ulcerative colitis and neurological diseases such as amyotrophic lateral sclerosis and Alzheimer's disease. In this paper, we report on the design of potent and highly selective dihydropyrazole (DHP) RIP1 kinase inhibitors starting from a high-throughput screen and the lead-optimization of this series from a lead with minimal rat oral exposure to the identification of dihydropyrazole 77 with good pharmacokinetic profiles in multiple species. Additionally, we identified a potent murine RIP1 kinase inhibitor 76 as a valuable in vivo tool molecule suitable for evaluating the role of RIP1 kinase in chronic models of disease. DHP 76 showed efficacy in mouse models of both multiple sclerosis and human retinitis pigmentosa.

HETEROCYCLIC AMIDES AS KINASE INHIBITORS

Disclosed are compounds having the formula: wherein R1 and R2 are as defined herein, and methods of making and using the same.

COMPOUNDS, COMPOSITIONS AND METHODS

The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

HETEROCYCLIC AMIDES AS KINASE INHIBITORS

Disclosed are compounds having the formula: (I) wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.

N′-(Arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT6R) antagonists with unique structural features

The 5-HT6 receptor (5-HT6R) has been in the spotlight for several years regarding CNS-related diseases. We set out to discover novel, neutral 5-HT6R antagonists to improve off-target selectivity compared to basic amine-con

SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS

This invention concerns sulfonylpyrazoline carboxamidine derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1), wherein the symbols have the meanings given in the description.

A diastereoselective synthesis of (dl)-1,3-diphenyl-1,3-propanediamines

A large-scale and practical synthesis of (dl)-1,3-diphenyl-1,3-propanediamine (1) has been achieved by a highly diastereoselective phenylcerium dichloride addition to 1-tert-butoxycarbonyl-4,5-dihydro-5-phenylpyrazole (3). Alkylcerium addition reaction to the corresponding 5-alkyl substituted 1-Boc-4,5-dihydropyrazoles was less satisfactory mainly giving ring-cleaved products. Further elaboration of the diamine 1 to the N-substituted derivatives 8a-f bearing N-methyl, N-ethyl, N-isopropyl, N-neopentyl, N-benzyl, and N-mesitylmethyl groups is described.